3-(乙基氨基甲酰基)苯甲酸 | 126926-33-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(乙基氨基甲酰基)苯甲酸
• 英文名称: m-(ethylaminocarbonyl)benzoic acid
• 英文别名: 3-(ethylcarbamoyl)benzoic acid
• CAS: 126926-33-8
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: KLAYVYFJJVHZEM-UHFFFAOYSA-N

物化性质

• 熔点：
  227 °C
• 沸点：
  411.1±28.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(乙基氨基甲酰基)苯甲酸 在 N-甲基吗啉 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  2-（胍基碘羰基）吡啶在水性溶剂中的氨基酸结合：一种比较复杂的结合研究，将复杂的稳定性与立体电子因子相关联。

  摘要：

  已合成了一系列胍基碘羰基吡啶受体，这些化合物结合DMSO水溶液中的氨基酸（羧酸盐形式），其缔合常数范围为K = 30至460 M（-1），这是通过NMR滴定实验确定的。借助计算出的复杂结构，可以将复杂稳定性的差异与空间效应和静电效应相关联。例如，吡啶氮孤对和结合的羧酸根之间的静电排斥使阴离子结合的效率比我们先前引入的用于水中羧酸根结合的类似吡咯受体的效率低。此外，如2b中的受体侧链与结合的底物之间的空间相互作用也不利于络合。

  DOI：

  10.1002/chem.200400652
• 作为产物：
  描述：

  间苯二甲酸单甲酯 在 水 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 90.17h， 生成 3-(乙基氨基甲酰基)苯甲酸
  参考文献：
  名称：

  [EN] THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS
  [FR] THIÉNO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES ET ANALOGUES COMME MODULATEUR DE SIRTUINE

  摘要：

  本文提供了新颖的替代噻吩[3,2-d]嘧啶-6-羧酰胺Sirtuin抑制剂及其使用方法。这些Sirtuin抑制剂可用于抑制Sirtuin介导的生物过程，例如用于治疗和/或预防包括但不限于癌症、神经退行性疾病和炎症在内的疾病和疾患。本文还提供了包含这些Sirtuin抑制剂的药物组合物以及包含Sirtuin抑制剂与另一种治疗药剂组合的组合物。

  公开号：

  WO2014138562A1
• 作为试剂：
  描述：

  methyl 3-(ethylcarbamoyl)benzoate 、 氢氧化锂 在 水 、 3-(乙基氨基甲酰基)苯甲酸 作用下， 以 甲醇 、 水 为溶剂， 反应 72.0h， 以to obtain 3-(ethylcarbamoyl)benzoic acid (Compound 62的产率得到3-(乙基氨基甲酰基)苯甲酸
  参考文献：
  名称：

  THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS

  摘要：

  本文提供了一种新型的取代噻吩[3,2-d]嘧啶-6-羧酰胺sirtuin抑制剂及其使用方法。这些sirtuin抑制剂可用于抑制sirtuin介导的生物过程，例如用于治疗和/或预防癌症、神经退行性疾病和炎症等疾病和疾患。本文还提供了包含这些sirtuin抑制剂的制药组合物和包含sirtuin抑制剂与另一种治疗剂的组合物。

  公开号：

  US20160002273A1

文献信息

• [EN] SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] PYRAZOLOAZÉPIN-4-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：LEO PHARMA AS

  公开号：WO2018108230A1

  公开（公告）日：2018-06-21

  The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

  本发明涉及具有磷酸二酯酶抑制活性的新型取代吡唑啉-4-酮化合物，以及它们作为治疗炎症性疾病和症状的治疗剂的用途。
• Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
  申请人：Fleck Roman Wolfgang

  公开号：US20090227588A1

  公开（公告）日：2009-09-10

  Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

  本发明涉及对可溶性环氧水解酶（sEH）活性的化合物，其组成物和使用和制备它们的方法。
• Discovery of Thieno[3,2-<i>d</i>]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3
  作者：Jeremy S. Disch、Ghotas Evindar、Cynthia H. Chiu、Charles A. Blum、Han Dai、Lei Jin、Eli Schuman、Kenneth E. Lind、Svetlana L. Belyanskaya、Jianghe Deng、Frank Coppo、Leah Aquilani、Todd L. Graybill、John W. Cuozzo、Siva Lavu、Cheney Mao、George P. Vlasuk、Robert B. Perni

  DOI：10.1021/jm400204k

  日期：2013.5.9

  The sirtuins SIRT1, SIRT2, and SIRT3 are NAD(+) dependent deacetylases that are considered potential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders. Encoded library technology (ELT) was used to affinity screen a 1.2 million heterocycle enriched library of DNA encoded small molecules, which identified pan-inhibitors of SIRT1/2/3 with nanomolar potency (e.g., 11c: IC50 = 3.6, 2.7, and 4.0 nM for SIRT1, SIRT2, and SIRT3, respectively). Subsequent SAR studies to improve physiochemical properties identified the potent drug like analogues 28 and 31. Crystallographic studies of 11c, 28, and 31 bound in the SIRT3 active site revealed that the common carboxamide binds in the nicotinamide C-pocket and the aliphatic portions of the inhibitors extend through the substrate channel, explaining the observable SAR. These pan SIRT1/2/3 inhibitors, representing a novel chemotype, are significantly more potent than currently available inhibitors, which makes them valuable tools for sirtuin research.
• Microsomal metabolism of<i>N</i>,<i>N</i>-diethyl-<i>m</i>-toluamide (DEET, DET): the extended network of metabolites
  作者：LUIS CONSTANTINO、JIM ILEY

  DOI：10.1080/004982599238588

  日期：1999.1

  1. The aim was to set out to establish the complete network of metabolites arising from the phenobarbital-treated rat liver microsomal oxidation of N,N-diethyl-m-toluamide (DEET). The products formed from DEET and all its subsequent metabolites were identified by HPLC retention times, UV spectroscopy, mass spectrometry and by comparison with authentic standards.2. DEET (1a) produces three major metabolites, N-ethyl-m-toluamide (1b), N,N-diethyl-m-(hydroxymethyl)benzamide (2a) and N-ethyl-m-(hydroxymethyl)benzamide (2b), and, at low substrate concentrations or extended reaction times, two minor metabolites, toluamide (1c) and N,N-diethyl-m-formylbenzamide (3a). 1b and 2a are primary metabolites and their formation follows Michaelis-Menten-type kinetics. At low DEET concentrations, ring methyl group oxidation is favoured; at saturation concentrations, methyl group oxidation and N-deethylation proceed at similar rates. The rate of formation of 2b decreases with increasing DEET concentration; 2b is therefore a secondary metabolite of DEET and DEET acts as a competitive inhibitor of the metabolism of 1b and 2a.3. Except for the primary amides, where N-dealkylation is impossible, metabolism of all subsequent compounds, 1b,c, 2a-c, 3a-c and 4a,b, involves an N-deethylation (NEt2 --> NHEt or NHEt --> NH2) competitive with a ring substituent oxidation (CH3 --> CH2OH, CH2OH --> CHO or CHO --> CO2H). Surprisingly, the aldehydes 3a-c are also reduced to the corresponding alcohols 2a-c (CHO --> CH2OH); CO inhibits the oxidative metabolism of 3a-c, bur reduction to 2a-c continues uninhibited.4. The outcomes of this work are that (1) previously unreported aldehydes 3b and 3c form part of the DEET network of metabolites, (2) the reduction of the aldehydes 3a-c has the potential to inhibit the formation of the more highly oxidized DEET metabolites, (3) amide hydrolysis was not observed for any substrate acid (4) no evidence was obtained for N-(1-hydroxyethyl)amide intermediates.
• SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
  申请人：Leo Pharma A/S

  公开号：EP3551633A1

  公开（公告）日：2019-10-16